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Summary
 
The mechanisms underlying initiation and maintenance of CD4 T cell responses after DNA
vaccination were studied using a construct coding for nonsecreted fifth component of comple-
ment (C5) protein, thus restricting the availability of antigen. The only cell types to express C5
were keratinocytes at the site of DNA application and a small number of dendritic cells present
in the draining lymph nodes. Antigen expression persisted for up to 12 wk in keratinocytes, but
dendritic cells did not express C5 beyond 2 wk after vaccination. Cross-priming of dendritic
cells by C5 expressed in keratinocytes did not occur unless keratinocyte death was induced by
irradiation in vitro. CD4 T cells were activated in the draining lymph nodes only and subse-
quently migrated to the spleen, where memory T cells persisted for longer than 40 wk despite
the absence of a source of persistent antigen. While DNA vaccination resulted in transfection
of a small proportion of dendritic cells only, it led to general activation of all dendritic cells,
thus providing optimal conditions for effective T cell activation and maintenance of memory. 
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G
 
enetic immunization with naked DNA has been
shown to induce humoral as well as cellular immune
responses with high efficiency, emphasizing the enormous
potential of this strategy for vaccination purposes (1). DNA
applied either intramuscularly or intradermally is mostly
taken up by muscle cells or keratinocytes, respectively (2,
3). However, these cells are unable to initiate primary T
cell responses. Several recent studies have provided evi-
dence for the involvement of dendritic cells (DC)
 
1
 
 in prim-
ing naive T cells after DNA vaccination (4–6). In many
cases, the constructs used for vaccination led to secretion of
the synthesized protein, so that it remained unclear to what
extent DC participated in stimulating an immune response
after direct transfection or through taking up antigen re-
leased by other transfected cells.
Successful priming of T cell responses generally requires
the presence of adjuvant, whose role appears to lie in acti-
vating APCs. This is especially the case for CD8 T cells
which are strictly dependent on T cell help unless they in-
teract with activated DC (7–9). Resting DC can be acti-
vated by inflammatory cytokines, bacterial products, and
certain viruses, resulting in upregulation of MHC class II
molecules and costimulatory molecules (10). Unmethylated
CpG motifs in nonvertebrate DNA have been described to
have a potent adjuvant effect (11–15). Here we show that
vaccination with a DNA construct encoding a protein that
is not secreted induces strong, long-lived CD4 T cell re-
sponses that are initiated in the draining lymph nodes by a
small number of DC that express the antigen. Although
DNA vaccination results in direct transfection of only a
very small proportion of DC, it leads to general activation
of all DC found in the draining lymph nodes, thus provid-
ing optimal conditions for effective T cell activation.
 
Materials and Methods
 
Mice
 
A/J (C5
 
2
 
) mice were maintained under specific pathogen-free
conditions at the National Institute for Medical Research, Lon-
don. A18 TCR transgenic Rag-1
 
2
 
/
 
2
 
 C5
 
2
 
 mice recognize
epitope 106-121 of the serum protein C5 in the context of H2-
E
 
k
 
 using a receptor composed of V
 
b
 
8.3 and V
 
a
 
11.1
 
a
 
 as described
previously (16).
 
BrdU Labeling and Detection
 
For continuous BrdU labeling, mice received one i.p. injec-
tion of 1 mg BrdU (Sigma Chemical Co.) in PBS and then were
given 0.8 mg/ml BrdU in the drinking water, which was
 
1
 
Abbreviations used in this paper:
 
 CFSE, carboxyfluorescein diacetate-suc-
cinimidylester; CMV, human cytomegalovirus; DC, dendritic cells; GFP,
green fluorescent protein; RT, reverse transcriptase. 
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changed every 3 d. Single cell suspensions of lymph node or
spleen were stained with anti-CD4 (PharMingen) and anti-
V
 
b
 
8.3 mAb (17), and resuspended in 200 
 
m
 
l of PBS/1%
paraformaldehyde for 20 min on ice. After washing with PBS,
the samples were fixed with cold 70% ethanol for 4 min, fol-
lowed by another fixation step with 100 
 
m
 
l of PBS/1% parafor-
maldehyde/0.01% Tween 20 for 30 min at room temperature
followed by 30 min on ice, and washed with PBS. Subsequently,
the samples were treated with DNase I (Boehringer Mannheim),
200 
 
m
 
l/sample for 30 min at 37
 
8
 
C. After washing with PBS, the
cells were resuspended in 45 
 
m
 
l of PBS/5% FCS/0.5% Tween 20
and stained with anti-BrdU mAb (Becton Dickinson).
 
Confocal Microscopy
 
Positively selected DC from draining lymph nodes of mice
vaccinated with green fluorescent protein (GFP)-C5 vaccine were
stained with biotinylated N418, followed by Streptavidin Texas
red (PharMingen). After washing with PBS, cells were dropped
onto glass coverslips and mounted on glass slides with colorless
nail lacquer. The confocal images were acquired at the Confocal
and Image Analysis Lab at the National Institute For Medical Re-
search, London. The confocal system used was an upright Leica
TCS-NT with an Argon/Krypton laser source.
 
Construction of DNA Vaccine
 
The full-length C5 cDNA (5.4 kb) was cloned into pTracer
vector (Invitrogen BV, UK) under the human cytomegalovirus
(CMV) promoter. To optimize and positively regulate the ex-
pression, 0.9 kb of 5
 
9
 
 untranslated intronic sequence of the im-
mediate early gene of cytomegalovirus (intron A) was cloned in
between the CMV promoter and C5 cDNA (18). In brief, C5
cDNA in pBluescript (Stratagene Inc.) was digested with
Bsp120I/NotI restriction enzymes, followed by separation of C5
from the agarose gel electrophoresis and the 5.4-kb fragment re-
leased from the construct was excised from the gel and purified
using the Geneclean protocol (Anachem Ltd., UK). The pTracer
vector was linearized using a unique NotI site in the multiple
cloning region of the plasmid and the terminal phosphates were
removed using Shrimp Alkaline Phosphatase, (Boehringer Mann-
heim) treatment for 30 min at 37
 
8
 
C, followed by purification of
the linearized vector by the Geneclean method. The 5.4-kb
NotI/Bsp120I–C5 DNA fragment and the NotI linearized/phos-
phatased vector were ligated together in a 3:1 ratio, respectively,
using T4 DNA ligase as per standard protocol. The ligated plas-
mid was then transformed into 
 
Escherichia coli
 
 bacterial DH5
 
a
 
 and
plasmid was purified as described in QIAGEN plasmid purifica-
tion hand book (QIAGEN, Ltd., UK).
 
Vaccination
 
DNA vaccine (
 
z
 
150 
 
m
 
g/mouse in 100 
 
m
 
l volume) was applied
by scarification of the ear skin with a 25G needle. At various time
points after vaccination, the cervical lymph nodes were removed for
further analysis. Keratinocytes were prepared by digesting the dorsal
halves of ears with 0.25% trypsin for 25 min at 37
 
8
 
C. Trypsin was
washed out with 20% FCS Iscove’s modified Dulbecco’s medium
and the epidermal sheets were peeled off with forceps, resuspended
in culture medium, or lysed for RNA preparation.
 
Immunization
 
Mice were injected subcutaneously above the footpads with 10
 
m
 
g C5 in complete Freund’s adjuvant. For determination of anti-
 
bodies, microtiter ELISA plates were coated with C5 at 10 
 
m
 
g/
ml (50 
 
m
 
l) in carbonate buffer, pH 9.5, and serial dilutions of se-
rum were tested for the presence of anti-C5 antibodies using sec-
ondary alkaline phosphatase–coupled anti-IgG1 and -IgG2a anti-
bodies.
 
FACS
 
®
 
 Analysis
 
Analytical flow cytometry was carried out using a FACScan
 
®
 
(Becton Dickinson) and the data were processed using the
Cellquest software (Becton Dickinson). Three color staining per-
formed with FITC-, PE-, and biotin-conjugated mAbs followed
by streptavidin red 670 (GIBCO BRL, Paisley, UK). Anti-CD4
(H129.19, PharMingen) was used as PE-conjugate, anti-TCR
V
 
b
 
8.3 (7G8.2) was conjugated with FITC using standard pro-
cedures. Biotinylated anti-CD44, -CD69, -CD62-L (PharMin-
gen) were used followed by streptavidin red 670.
 
Magnetic Cell Sorting
 
Positive selection of lymph node cells was carried out by mag-
netic cell sorting with the Vario-MACS (Miltenyi Biotec Inc.,
Germany) according to the manufacturer’s instructions. Lymph
nodes were digested with a cocktail of 0.1% DNase I (fraction
IX; Sigma Chemical Co.) and 1.6 mg/ml collagenase (CLS4;
Worthington Biochemical Corp.) at 37
 
8
 
C for 1 h. For positive
selection of DC, cells were stained with biotinylated N418 (19),
followed by labeling with streptavidin-magnetic beads. Positively
selected cells and the nonselected fractions were collected for fur-
ther analysis.
 
cDNA Generation, Amplification, and Analysis
 
For generation of cDNA, cells were lysed and total RNA was
extracted from the lysate in the presence of RNase inhibitors ac-
cording to the RNeasy RNA isolation kit manual (QIAGEN,
Ltd.). cDNA was generated from the mRNA template using a
15-mer poly dT oligonucleotide (Genosys Biotechnologies, Ltd.)
and the Superscript reverse transcriptase (RT) enzyme according
to Superscript Preamplification System protocol (GIBCO BRL).
Expression of the C5 construct was detected by PCR using
C5-specific primers under general PCR conditions.
 
Functional T Cell Activation Tests
 
IL-2 Production by T Cells from Injected Mice.
 
Draining lymph
nodes from vaccinated or protein injected mice were digested
with collagenase/DNase cocktail (see above), washed, and 2 
 
3
 
10
 
5
 
 lymphocytes were cultured in round-bottom 96-well plates
with 2 
 
3
 
 10
 
4
 
/well bone marrow–derived DC and C5 antigen.
Bone marrow–derived DC as APC were generated as described
previously (20). In some cases (see Fig. 2 E) DC were pulsed with
antigen for 2 h, followed by extensive washing to minimize carry
over of antigen into the culture. After 48 h of culture, 50 
 
m
 
l of
supernatants were transferred to IL-2–dependent CTLL ATCC
TIB 214 cells, and CTLL proliferation was assessed by [
 
3
 
H]thymi-
dine incorporation over 18 h.
 
IL-2 Production by A18 T Cell Hybridoma Cells.
 
5 
 
3
 
 10
 
4
 
/well
A18 hybridoma cells were cultured with APC as indicated for
24 h. Supernatants were then tested for the presence of IL-2 as
described above.
 
Limiting Dilution Assay.
 
For assessment of C5-specific T cell
precursors, serial dilutions of spleen cell suspensions (24 replicates
for each cell concentration) were cultured in the presence of 2 
 
3
 
10
 
4
 
 bone marrow–derived DC and 10 
 
m
 
g C5 protein in Iscove’s 
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modified Dulbecco’s medium (Sigma Chemical Co.) containing
5% FCS, 2 
 
3
 
 10
 
2
 
3
 
 M 
 
l
 
-glutamine, 100 U/ml penicillin, 100 
 
m
 
g/
ml streptomycin, 5 
 
3
 
 10
 
2
 
5
 
 M ME (all from Sigma Chemical
Co.). Control wells received T cells and DC, but not C5 protein.
After 48 h of culture, 50 
 
m
 
l of supernatants was transferred to IL-
2–dependent CTLL cells, and CTLL proliferation was assessed by
[
 
3
 
H]thymidine incorporation over 18 h. Reactions were consid-
ered positive in wells that exhibited proliferation greater than the
mean plus three times the standard deviation value of control
wells. The frequency of antigen-specific cells was calculated by
regression analysis of the number of negative wells at each dilu-
tion of responder cells.
 
Keratinocyte/DC Cocultures.
 
Ear cell suspensions were added
to 6-well Costar plates (40 mm diameter) and allowed to adhere
for 2 h. Nonadherent cells were washed off and some of the kera-
tinocyte monolayers were subjected to 1,000 Rad irradiation be-
fore addition of 10
 
6
 
/well bone marrow–derived DC. Kerati-
nocyte/DC mixtures were incubated overnight. The DC were
then washed off and added in serially titrated numbers to 5 
 
3
 
10
 
4
 
/well A18 T hybridoma cells. IL-2 production by hybridoma
cells was determined 24 h later.
 
Results
 
Induction of Long-lived CD4 T Cell, But Not B Cell Re-
sponses with DNA Vaccine Encoding Intracellularly Expressed
C5 Protein.
 
The DNA construct 5.4 containing full-
length C5 cDNA under control of the human CMV pro-
moter was applied to the ears of mice by scarification. Con-
trol mice were vaccinated with the corresponding empty
vector DNA or with C5 protein in CFA. 10 d later the
draining lymph nodes were taken and tested in vitro for
generation of C5-specific T cell responses. 5.4 vaccination
and immunization with C5 protein generated C5-specific
T cell responses upon restimulation with C5 protein in vitro,
whereas mice vaccinated with empty vector did not mount
a response (Fig. 1 A). However, only mice that had re-
ceived C5 protein had generated C5-specific antibodies 3 wk
later, although splenocytes from both groups generated
strong C5-specific T cell responses upon restimulation in
vitro (data not shown). To increase the chance for an anti-
body response, two mice from each group were reimmu-
nized 3 wk after protein immunization or 5.4 vaccination
with either C5 protein or vaccine and then bled for assess-
ment of the antibody responses to C5 9 d later. As shown
in Fig. 1 B, C5 protein–immunized mice produced anti-C5
antibodies of the IgG1 subclass as previously reported (21),
whereas 5.4-vaccinated mice did not produce C5-specific
antibodies of any subclass even after revaccination. We fol-
lowed precursor frequencies for C5-specific IL-2 produc-
ing T cells in a cohort of 5.4-vaccinated mice for 40 wk
and found that maximal frequencies are detectable around
4 wk after vaccination and decline slowly thereafter, but
still remain above nontreated background controls at 40 wk
after vaccination (Table I).
 
DC Isolated from Draining Lymph Nodes of Vaccinated Mice
Express C5 Protein.
 
DC from 5.4- and vector control–
vaccinated mice were isolated by magnetic cell sorting
from draining lymph node cells and spleen and then as-
Figure 1. (A) IL-2 production
of cells from draining lymph
nodes of 5.4-vaccinated (150
mg/mouse, r), control vector–
vaccinated (s), or protein-
immunized (10 mg in CFA, u)
mice. Lymph nodes from two
mice per group were pooled.
The figure shows proliferation of
IL-2–dependent CTLL cells. (B)
Two 5.4-vaccinated (r) and
two C5 protein–immunized (u)
mice were revaccinated or rein-
jected with 10 mg C5 protein/
CFA, respectively, 3 wk after the
first injection. 9 d later their sera
were tested for the presence of
IgG1 and IgG2a anti-C5 anti-
bodies by ELISA.
 
Table I.
 
Frequency of C5-specific T Cells per 10
 
6
 
 Spleen Cells
 
Weeks after 
vaccination Untreated DNA vaccinated
A18TCRtg 
untreated
0 5 5 10,000
4 5.7 110 13,333
8 5 66.6 10,000
12 5 50 8,000
16 5.7 30 13,333
20 5 25 10,000
24 5.7 25 10,000
28 5 25 8,000
32 5 25 10,000
36 5 25 13,333
40 5 25 10,000
The frequency of C5-specific T cells per 10
 
6
 
 spleen cells was calculated
by regression analysis of the number of negative wells (24 replicates per
cell concentration) at each dilution of responder cells. 
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sessed for the expression of C5 by RT-PCR. In addition, a
suspension of ear skin cells (containing mainly kerati-
nocytes) was analyzed by RT-PCR. As shown in Fig. 2 A
DC from draining lymph nodes, but not spleen of 5.4-vac-
cinated mice, express C5. Keratinocytes from the ears of
5.4-vaccinated mice also showed a positive RT-PCR.
There was no C5 message detectable in DC from vector
vaccinated–control mice. Furthermore, the cell population
depleted of DC from draining lymph nodes of 5.4-vacci-
nated mice, containing B and T cells, did not show a posi-
tive RT-PCR signal. This indicates that, in 5.4-vaccinated
mice, a proportion of DC, which presumably migrated
from the site of DNA application to the draining lymph
nodes, had taken up the DNA construct and synthesized
C5 protein. With the exception of keratinocytes at the site
of DNA application no other cell population was found to
Figure 2. (A) RT-PCR was
performed for C5 and b-actin
for each sample, as indicated on
top. The panel on the left shows
RT-PCR from cells of 5.4-
vaccinated mice. NDC-DC de-
pleted lymph node cells. On the
right RT-PCR from DC of
control vector–vaccinated mice
and from keratinocytes of 5.4-
vaccinated mice are shown. (B
and C) Quantitative PCR for
the presence of C5 cDNA in (B)
lymph nodes and (C) spleen of
5.4-vaccinated mice. The num-
ber of PCR cycles is indicated
below each lane. (D) Confocal
image of two DC isolated from
draining lymph nodes of 5.4-
vaccinated mice. N418 expres-
sion is in red, green fluorescence
(GFP) shows the presence of the
vaccination construct. Bright
field image is overlaid to illus-
trate the dendritic shape of the
cells. (E) IL-2 production ob-
tained with 2 3 104/well DC
isolated from draining lymph
nodes of vaccinated mice deter-
mined by comparison with a
standard curve. The standard
curve was set up by culturing
mixtures of untreated and C5-
pulsed (and extensively washed)
bone marrow–derived DC with
A18 hybridoma cells. The ratio
of unpulsed/pulsed DC is shown
on the abscissa, and the counts
obtained by coculture of A18 hybridoma cells and DC from vaccinated mice intersects the standard curve at a ratio of 98 unpulsed to 2 pulsed DC. (F) IL-2
production by A18 hybridoma cells cultured with serially titrated numbers of DC which were either pulsed with 5 mg/ml C5 (---s---) or cocultured
with untreated keratinocytes (u) or with 1,000 Rad irradiated keratinocytes (e). 
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contain C5 message. In contrast to this, C5 DNA was de-
monstrable in lymph node and spleen, albeit at much
smaller amounts in the latter (Fig. 2, B and C). This sug-
gests that DNA applied to ear skin gains access to the circu-
lation.
 
A Small Proportion of DC Is Transfected and Cross-presenta-
tion of Protein from Transfected Keratinocytes Occurs Only in a
Situation of Excessive Cell Death.
 
In an attempt to quantify
the number of DC in draining lymph nodes which express
the C5 construct, we set up functional studies and confocal
analysis. The 5.4 construct used contains GFP expressed
under a second promoter to allow direct visualization of
transfected cells by fluorescence microscopy. FACS
 
®
 
 analy-
sis of DC isolated by magnetic cell sorting 10 d after vacci-
nation did not give a clear signal, presumably because of
the very low incidence of transfection. However, GFP
containing DC were clearly identifiable by confocal mi-
croscopy (Fig. 2 D). DC from draining lymph nodes of
5.4-vaccinated mice were then tested for their capacity to
activate the C5-specific T cell hybrid A18. In parallel a
standard curve was set up by combining various numbers of
DC that had been pulsed with C5 protein, followed by
washing, with nonpulsed DC and A18 T cells. Comparing
the T cell responses obtained, we estimate that 
 
z
 
2% of
the DC in the draining lymph nodes of vaccinated mice
processed and presented C5 in the context of MHC class II
molecules for recognition by A18 T cells (Fig. 2 E). A re-
cent study (4) also illustrated that DC from vaccinated mice
could stimulate T cells in the absence of added antigen.
However, in this case the protein encoded by the DNA
construct was secreted so that it was not possible to define
to what extent the stimulatory capacity of DC was due to
direct transfection, compared with uptake of protein syn-
thesized and released by other transfected cells. Although
the 5.4 C5 construct does not give rise to secreted C5 pro-
tein, there is now substantial evidence that DC can take up
protein from other cells by a mechanism referred to as
cross-priming (22–24). We tested this by coculturing kera-
tinocytes from 5.4-vaccinated mice with untreated DC
which were subsequently assayed for their ability to activate
the A18 hybrid. This coculture assay is very sensitive, de-
tecting as little as 6 ng/ml C5 (25), but in the presence of
intact keratinocytes, which expressed C5 as shown by RT-
PCR, there was no evidence of any protein transfer to DC
(Fig. 2 F). In contrast, exposure of keratinocytes to 1,000
Rad irradiation before coculture with DC resulted in
strong C5 presentation by the DC. This indicates that
cell death induced by this treatment allows cross-priming
of dendritic cells for presentation in the context of MHC
class II.
 
DNA Vaccination Results in Activation of DC.
 
DC isolated
by magnetic cell sorting from draining lymph nodes of 5.4-
or control vector–vaccinated mice were tested for expres-
sion of cell surface molecules that are important in T cell
stimulation, such as CD40, B7.1, B7.2, and ICAM-1. Both
5.4 vaccine and vector resulted in strong upregulation of
these molecules on all DC found in the draining lymph
nodes compared with DC from untreated controls (Fig. 3),
illustrating that DNA vaccination, in a nonspecific manner,
provides the necessary stimuli for activation of DC; this is
in accordance with recent observations that bacterial DNA
and synthetic CpG oligodeoxynucleotides promote DC ac-
tivation and maturation in vitro (26).
 
Kinetics and Site of T Cell Activation after DNA Vaccination
of Transgenic Mice.
 
To investigate the sites, kinetics, and
extent of T cell activation after DNA vaccination, we made
use of T cell receptor transgenic (A18 TCRtg) mice, as
normal mice have very low precursor frequencies for C5-
specific T cells (Table I). All CD4 T cells found in the A18
TCRtg strain on a Rag
 
2
 
/
 
2
 
 background are specific for
epitope 106-121 of C5 (16) and have a naive phenotype as
evidenced by their low expression of CD44 and CD69 and
high expression of CD62-L. A cohort of A18 TCRtg mice
was vaccinated with the 5.4 or vector control construct. At
the same time two vaccinated mice per group were in-
jected with BrdU and received BrdU in the drinking water
for the next 3 d. 3 d later, the draining lymph nodes and
spleens from BrdU-treated mice were analyzed for expres-
sion of activation markers on CD4 T cells and incorpora-
tion of BrdU. In 5.4-vaccinated mice, all CD4 T cells from
lymph nodes draining the site of vaccination had incorpo-
rated BrdU, indicating activation and division (Fig. 4 A).
CD69, an early activation marker, was upregulated and
CD62-L showed some degree of downregulation, whereas
no significant changes were observed in CD44 levels yet.
Figure 3. FACS® analysis of DC
isolated 3 d after vaccination by mag-
netic cell sorting from draining lymph
nodes of 5.4-vaccinated (thick lines),
vector-vaccinated (thin lines), and un-
treated mice (shaded histograms). The
figure shows expression of activation
markers B7.1, B7.2, CD40, and
ICAM-1 on gated N418 positive DC. 
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CD4 T cells from mice vaccinated with vector control
construct or from untreated mice retained their naive phe-
notype. Whereas CD4 T cells from draining lymph nodes
of 5.4-vaccinated mice all appear to be activated 3 d after
vaccination, splenic CD4 T cells had neither incorporated
BrdU nor showed any changes in activation markers. This
indicates that T cell activation is initiated in the draining
lymph nodes and that, in contrast to DC, antigen-specific T
cells are only activated by DNA encoding the correspond-
ing antigen; there was no nonspecific activation by vector
DNA alone. By day 15 after vaccination, all CD4 T cells in
lymph node and spleen of 5.4-vaccinated mice expressed an
activated phenotype, characterized by downregulation of
CD62-L and upregulation of CD44 (Fig. 4 B), whereas T
cells in control mice showed no signs of activation.
 
The Source of Stimulatory Antigen Is Short-lived in Vaccinated
Mice.
 
To test for the continuous presence of antigen in
5.4-vaccinated mice, two approaches were used. First, DC of
the draining lymph nodes and keratinocytes at the site of in-
jection were analyzed for expression of C5 by RT-PCR from
1 to 20 wk after vaccination. Fig. 5 shows that, for DC, C5
expression was not demonstrable later than 2 wk after vaccina-
tion, whereas keratinocytes continued to express C5 longer,
until week 12. In addition, a sensitive in vivo test using naive
transgenic A18 T cells was used to detect the presence of a
persistent source of antigen for T cell priming. Naive A18 T
cells carrying a different Thy 1 allotype (Thy1.1) and labeled
with the fluorescent dye carboxyfluorescein diacetate-succin-
imidylester (CFSE) to allow monitoring of cell division (27)
were injected into host mice that had been vaccinated 20 d
Figure 5. RT-PCR analysis
was performed for keratinocytes
from (A) 5.4-vaccinated mice
and (B) DC isolated from drain-
ing lymph nodes of 5.4-vacci-
nated mice by magnetic cell sort-
ing. RT-PCR was performed
for C5 and b-actin at different
time points after vaccination, as
indicated on top (week 1 to
week 20). The third lane for
each time point is a control
showing the absence of DNA
contamination in the RNA sam-
ples (omission of RT before the
PCR reaction).
 
Figure 4.
 
Lymph node and spleen cells from A18 TCRtg mice vaccinated with the 5.4 con-
struct, (thick lines), the control vector (thin lines), or untreated (shaded histograms) were ana-
lyzed (A) 3 d and (B) 15 d later by three-color FACS
 
® analysis. The figure shows expression of
CD44, CD62-L and CD69 (and BrdU labeling for day 3 after vaccination) on gated CD4 and
Vb8.3-positive T cells.175 Akbari et al.
before. 7 d after injection, the mice were killed and the phe-
notype of the injected T cell population was analyzed in
FACS® (Fig. 6). Thy1.1 A18 T cells found in the draining
lymph nodes of mice vaccinated 20 d before had retained their
CFSE label and naive phenotype. Likewise, injected Thy1.1
A18 T cells present in the spleen had a naive phenotype (data
not shown). Thus, it appears that 20 d after vaccination there
is no longer any source of stimulatory antigen present.
Discussion
The success of DNA vaccination is linked to initiation of
T cell responses by DC. There are various routes by which
DC can obtain the protein they present. They can either
take up protein secreted by other cell types which were
transfected after DNA vaccination, or pick up antigen from
transfected cells, an as yet ill-defined mechanism referred to
as cross-presentation (24, 28, 29). Additionally, they can be
transfected themselves (2, 5, 6). In this paper we used a
DNA construct encoding a form of C5 protein which is
not secreted by transfected cells with the aim to limit its ac-
cessibility to APCs and investigate the consequences for
priming and maintenance of CD4 T cell responses. It is not
known what causes the block in secretion of C5, but we
determined recently that addition of an optimal leader se-
quence to the construct results in C5 secretion. The exclu-
sive intracellular expression of the 5.4 construct after trans-
fection into many different cell types, such as fibroblasts, B
cells, macrophages, and hepatocytes, has been tested exten-
sively (25). In addition, its restricted localization is supported
by the absence of antibody responses after vaccination. Thus,
C5 message was only detectable in keratinocytes at the site of
vaccination and in a small proportion of DC within the
draining lymph nodes. We assume that these migrated there
from the site of DNA application in the ear skin, although
we cannot exclude the possibility that DC also were trans-
fected in the draining lymph nodes themselves because of
relatively high levels of DNA at this site (Fig. 2 B). Func-
tional analysis of their stimulatory capacity for C5-specific T
cells suggested that z2% of the lymph node DC presented
antigen. A recent study (6) likewise concluded that activa-
tion of CD8 T cells is achieved through direct transfection of
a small proportion of DC that migrate from the skin to the
draining lymph nodes. Although it is possible that this re-
flects the number of directly transfected DC, we cannot for-
mally exclude the possibility that some of these DC acquired
C5 protein expressed in keratinocytes by cross-presentation.
Notably, no antigen was transferred to DC from intact kera-
tinocytes, whereas irradiation of keratinocytes provided a
strong stimulus for cross-presentation.
It is still a matter of debate whether normal cell turnover
by apoptosis in vivo results in release of antigenic material
which could be obtained for presentation by DC or
whether this event only occurs in inflammatory situations
encountered during necrosis of cells or tissue (30), or in in-
fection induced apoptosis as described by Albert et al. (22).
While there is no obvious sign of inflammation, such as
swelling after scarification of the ears, it is nevertheless pos-
sible that some keratinocytes die in a manner that results in
cross-presentation by skin DC, which then migrate to the
draining lymph nodes to activate T cells. However, this
event is unlikely to take place at later time points after vac-
cination when the site of scarification has healed.
Although keratinocytes were shown to express C5 up to
12 wk after vaccination, the presence of antigen in these
cells is unlikely to be responsible for the persistence of T
cell memory beyond 40 wk. DC have been described to
have a half-life of ,1 wk in mouse spleen, and those DC
present in lymphoid organs no longer proliferate (31, 32).
We found no evidence of C5 expressing DC in the spleen,
indicating that the transfected DC found in draining lymph
nodes do not migrate to other lymphoid organs. The ab-
sence of C5 expression in DC beyond 2 wk after vaccina-
tion, together with the fact that a fresh cohort of naive
transgenic T cells failed to be activated when injected into
mice that had been vaccinated 20 d before, support the
conclusion that there is no long-lived source of antigenic
material present. Considering the absence of an antibody
response, it is also unlikely that antigen was stored in the
form of antigen–antibody complexes on follicular DC,
which are known to be highly efficient depots of long-
lived antigen (33). Therefore, it seems that DNA vaccina-
tion can induce memory CD4 T cells that can be long-
lived without repeated antigenic stimulation.
The potent immunostimulatory activity of unmethylated
CpG motifs present in bacterial plasmid DNA (for review
Figure 6. Three-color FACS®
analysis of cells from draining
lymph nodes (pooled from two
mice vaccinated with 5.4 20 d be-
fore i.v. injection with 106 CFSE-
labeled naive Thy1.1 A18 TCRtg
T cells). 7 d after injection of naive
T cells, lymph node cells were an-
alyzed by FACS® for expression of
CFSE, Thy1.2, Thy1.1, and acti-
vation markers. The dot plot
shows CFSE levels on Thy1.2
negative (Thy1.1 positive) injected
T cells. Histograms for the activa-
tion markers CD44 and CD62-l
show cells gated for expression of
Thy1.1 (black lines) or Thy1.2
(endogenous T cells; shaded histo-
grams).176 Dendritic Cells in DNA Vaccination
see reference 34) may have important implications for
priming and maintenance of T cell responses. The data in
this paper show that DNA provides activation signals to
DC. While only a very low fraction of DC expressed C5,
all DC in the draining lymph nodes showed an activated
phenotype. It is highly likely that scarification itself pro-
vided an activation signal to Langerhans cells in the skin,
provoking them to migrate to the draining lymph nodes.
However, it is unlikely that all DC found in the draining
lymph nodes were derived from Langerhans cells, suggest-
ing instead that DNA present in the lymph nodes was re-
sponsible for activation of resident DC and DC that may
have been recruited from the circulation. Influx of DC or
expansion from precursors may take place after DNA vac-
cination since total DC numbers in draining lymph nodes
increase (6). It has been reported that DNA vaccines ad-
ministered by the gene gun method gain access to the cir-
culation, because immediate removal of the ear after vacci-
nation does not prevent an immune response (35, 36). This
seems to happen after scarification as well, since PCR anal-
ysis showed strong positive signals for C5 DNA in lymph
node and weaker expression in spleen. Therefore, small
amounts of DNA reaching the circulation apparently exert
stimulatory activity on many cell types, but fail to be tran-
scribed and translated into protein.
In view of recent data showing the crucial importance of
DC activation for stimulation of CD8 T cell responses, the
finding that DNA vaccination nonspecifically activates a
large number of dendritic cells suggests that this type of ge-
netic immunization provides ideal conditions not only for
CD4 T cell responses, but especially for the initiation of
CD8 T cell responses. Therefore, the success in achieving
long-lived memory responses by DNA vaccination may lie
in optimal activation and expansion of most antigen-spe-
cific T cell precursors, rather than in long-term storage of
antigen leading to periodic restimulation.
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